Generali Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Generali Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.79M	Buy	7,685 +181	+2%	+$123K	0.09%	204
2026 Q1	$5.8M	Sell	7,504 -162	-2%	-$124K	0.12%	167
2025 Q4	$5.92M	Sell	7,666 -4,354	-36%	-$2.96M	0.12%	159
2025 Q3	$6.76M	Sell	12,020 -664	-5%	-$375K	0.14%	133
2025 Q2	$6.66M	Buy	12,684 +1,650	+15%	+$921K	0.15%	144
2025 Q1	$7M	Sell	11,034 -324	-3%	-$223K	0.17%	123
2024 Q4	$8.09M	Buy	+11,358	New	+$9.53M	0.21%	109

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Generali Asset Management's REGN Position: Q2 2026 in Review

Generali Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 2.4% in Q2 2026, buying an estimated $123K and bringing the position to 7,685 shares worth $4.79M. The position accounts for 0.09% of the portfolio, ranked #204.

Generali Asset Management first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.09M in Q4 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Generali Asset Management held 7,685 shares of Regeneron Pharmaceuticals worth $4.79M as of Q2 2026.
Generali Asset Management bought 181 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $123K.
Regeneron Pharmaceuticals made up 0.09% of Generali Asset Management's portfolio in Q2 2026, its #204 holding.
Generali Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Generali Asset Management's Regeneron Pharmaceuticals position peaked at $8.09M in Q4 2024.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Generali Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.